Century Therapeutics, Inc. (NASDAQ:IPSC) Receives $14.17 Consensus Price Target from Analysts

Century Therapeutics, Inc. (NASDAQ:IPSCGet Free Report) has been given an average recommendation of “Moderate Buy” by the six research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $14.00.

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group raised their price target on shares of Century Therapeutics from $22.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Piper Sandler reissued an “overweight” rating and set a $9.00 price target (down previously from $10.00) on shares of Century Therapeutics in a research report on Friday. Finally, HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Century Therapeutics in a research report on Friday, March 15th.

Check Out Our Latest Stock Analysis on Century Therapeutics

Insiders Place Their Bets

In other news, insider Adrienne Farid sold 22,831 shares of the business’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $5.14, for a total transaction of $117,351.34. Following the completion of the transaction, the insider now owns 114,149 shares of the company’s stock, valued at $586,725.86. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 25,509 shares of company stock valued at $127,635 over the last 90 days. 7.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Century Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of IPSC. Citigroup Inc. boosted its holdings in shares of Century Therapeutics by 1,142.8% during the second quarter. Citigroup Inc. now owns 8,339 shares of the company’s stock valued at $26,000 after acquiring an additional 7,668 shares during the period. UBS Group AG bought a new stake in shares of Century Therapeutics during the fourth quarter valued at about $28,000. Wells Fargo & Company MN raised its stake in shares of Century Therapeutics by 148.5% during the second quarter. Wells Fargo & Company MN now owns 8,905 shares of the company’s stock valued at $28,000 after purchasing an additional 5,321 shares in the last quarter. Barclays PLC raised its stake in shares of Century Therapeutics by 533.3% during the fourth quarter. Barclays PLC now owns 5,408 shares of the company’s stock valued at $28,000 after purchasing an additional 4,554 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Century Therapeutics during the first quarter valued at about $30,000. Institutional investors and hedge funds own 50.20% of the company’s stock.

Century Therapeutics Price Performance

NASDAQ IPSC opened at $3.91 on Friday. The company has a market cap of $253.45 million, a P/E ratio of -1.71 and a beta of 1.33. Century Therapeutics has a 12 month low of $1.28 and a 12 month high of $5.51. The company has a 50-day moving average of $4.31 and a 200-day moving average of $3.07.

Century Therapeutics (NASDAQ:IPSCGet Free Report) last issued its earnings results on Thursday, March 14th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. Century Therapeutics had a negative return on equity of 54.73% and a negative net margin of 6,115.12%. The company had revenue of $0.27 million during the quarter, compared to the consensus estimate of $1.69 million. As a group, equities research analysts anticipate that Century Therapeutics will post -2.02 EPS for the current year.

About Century Therapeutics

(Get Free Report

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.

Featured Stories

Analyst Recommendations for Century Therapeutics (NASDAQ:IPSC)

Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.